Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Olutasidenib · Rezlidhia, FT-2102

Small molecule · Inhibitor of isocitrate dehydrogenase 1 (IDH1) (IDH1) · developed by Rigel Pharms

Approved FDA, Dec 2022
RIGL Developer
2 Registered trials

What is Olutasidenib?

Olutasidenib is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1), acting on mutant IDH1 enzymes such as R132H and R132C to reduce levels of 2-hydroxyglutarate in leukemia cells. It is used for acute myeloid leukemia with susceptible IDH1 mutations and is being studied in glioma, cholangiocarcinoma and other solid tumor malignancies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Rezlidhia, FT-2102
Drug type
Small molecule
Targets
isocitrate dehydrogenase 1 (IDH1) (IDH1)
Mechanism
Inhibitor of isocitrate dehydrogenase 1 (IDH1) (IDH1)
Pathways
2-hydroxyglutarate production
Therapy area
Oncology
Developer
Rigel Pharms (RIGL)
FDA status
Approved as Rezlidhia (December 1, 2022), NDA215814 · FDA label
UNII
0T4IMT8S5Z

✅ FDA-approved uses

From the indications section of the FDA label (version of Nov 5, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07486713 Phase 4 AML (Acute Myeloid Leukemia) Recruiting RIGL
NCT07130695 Phase 1 Acute Myeloid Leukemia Withdrawn RIGL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AML (Acute Myeloid Leukemia)CholangiocarcinomaGliomaSolid Tumor MalignanciesAcute Myeloid Leukemia

Other drugs acting on IDH1

More from Rigel Pharms

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the RIGL page.

Follow RIGL, the company behind Olutasidenib

See RIGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RIGL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.